Navigation Links
FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
Date:8/13/2008

6, the FDA approved the PROCLEIX ULTRIO assay to screen donated blood, plasma, organs and tissue for HIV-1 and HCV on Gen-Probe's semi-automated instrument system. In May of 2007, the FDA granted a similar approval to use the assay on the TIGRIS system.

However, the PROCLEIX ULTRIO assay was not approved to screen donated blood for HBV, as the initial pivotal study for the assay was not designed to, and did not, demonstrate HBV yield. Yield is defined as HBV-infected blood donations that were intercepted by the PROCLEIX ULTRIO assay, but that were initially negative based on serology tests for HBV surface antigen and core antibodies.

In early 2007, Gen-Probe and Chiron initiated post-marketing studies of the PROCLEIX ULTRIO assay to demonstrate the HBV yield required for a donor- screening claim. Based on the results of this study, Gen-Probe submitted a supplemental Biologics License Application to the FDA in February of 2008.

HBV is the most common serious liver infection in the world and is transmitted through contact with blood and body fluids. HBV infection can lead to liver failure, cirrhosis or cancer. According to the World Health Organization, more than 350 million people worldwide are chronically infected with HBV. More than one million people die annually as a result of HBV infections.

Trademarks

PROCLEIX and ULTRIO are trademarks of Novartis Vaccines and Diagnostics, Inc. TIGRIS is a trademark of Gen-Probe.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has approximately 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employ
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
2. US FDA Grants Pediatric Exclusivity for UCBs Keppra(R)
3. Xceed Molecular Grants Gen-Probe License to Xceeds Flow-Thru Chip(R) Technology for Multiplex Molecular Diagnostics
4. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
5. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
6. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
7. Susan G. Komen for the Cure(R) Announces Largest Grants Slate Ever: $100 Million to Speed Delivery of Breast Cancer Discoveries, Cures
8. European Union, State of Brandenburg, Award Grants to Alcat Europe, GmbH
9. FDA Grants Market Clearance to Aerocrine Inc.s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma
10. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
11. United States Patent Office Grants CryoCors Request for Patent Interference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... CHICAGO and RARITAN, N.J. ... the international, multi-center, open-label, two-part, single-arm Phase 2 ... – an investigational, human anti-CD38 monoclonal antibody – ... percent (95% CI, 20.8-38.9), as assessed by an ... multiple myeloma. The ORR was consistent among the ...
(Date:5/29/2015)... -- BerGenBio AS ("BerGenBio" or the "Company"), ... on the latest data on BGB324, the Company,s first-in-class, ... kinase, and BGB10C9, an Axl function-blocking monoclonal antibody in ... with the 2015 American Society of Clinical Oncology (ASCO) ... 29 - June 2, 2015. The abstract ...
(Date:5/29/2015)... London, UK (PRWEB) May 29, 2015 ... Co., Ltd. (Chem-Report ) signed a partnership agreement ... is now authorised to distribute and sell research ... Assistant Manager at Partners Department, commented upon the ... creating reports on key petroleum and chemical markets ...
(Date:5/29/2015)... , May 29, 2015  Caris Life Sciences ... fulfilling the promise of precision medicine, today announced ... demonstrate the clinical utility of Caris Molecular Intelligence ... service, in helping to identify targeted treatment options ... each of the studies, results of which are ...
Breaking Biology Technology:Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6
... Wis. - For the second time this year, a ... stock for sale to the public. Called an initial public ... to the companies and investors who are directly involved, but ... NimbleGen , a Madison-based biotechnology company, has filed papers with ...
... to experience high rates of failure. As a result, ... valued partner. The result stifles innovation, growth, and a ... requires shedding the flawed processes of yesterday, and introducing ... by promising incremental delivery of functional software. , , ...
... - Now that two companies he once owned ... strategy, Brian Wiegand's days as a self-described serial entrepreneur ... NameProtect , a developer of digital brand management ... of Wilmington, Del. , ,He will concentrate on ...
Cached Biology Technology:Wisconsin IPOs are a harbinger of growing tech economy 2Wisconsin IPOs are a harbinger of growing tech economy 3Agile Revolution: A new era of software delivery 2Agile Revolution: A new era of software delivery 3Agile Revolution: A new era of software delivery 4NameProtect sold, tech entrepreneur to focus on Jellyfish.com 2
(Date:5/19/2015)... Fingerprint Cards (FPC) has received an ... and FPC1035 from one if its module partners. Deliveries are ... 2015 and the sensors will be used by smartphone manufacturers ... 2015 hereby amount to 740 MSEK to date. In addition ... and a number of smaller orders not separately communicated amounting ...
(Date:5/19/2015)... 19, 2015 Research ... addition of the  "Genetic Testing Market Outlook ... http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic Testing ... of the current and future genetic testing ... their working principles and types are covered ...
(Date:5/14/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ... Sensors Market in Smart Mobile Devices " report ... 2014 was a watershed year for fingerprint sensors in ... Pay,. Apple gave fingerprint sensors a raison d,etre in ... sensors are a must-have feature in flagship smartphones. ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Genetic Testing Market Outlook 2018 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
... to put all your eggs in one basket unless you,re a ... Arizona and northern Mexico, the senita moth depends on a single ... and for a place to lay eggs. The senita cactus is ... flowers. Senita cacti and senita moths have a rare, mutually dependent ...
... A major surprise emerging from genome sequencing projects is ... as significantly less complex organisms such as the minute ... count is behind the genetic differences between simpler and ... cellular complexity can be explained, in large part, by ...
... (August 13, 2007) In some ways, certain tumors resemble bee ... tumor plays a specific role, and just a fraction of ... maintain themselves in an unspecialized state and seed new tumors. ... that form the bulk of the tumor. These ...
Cached Biology News:Which came first, the moth or the cactus? 2Which came first, the moth or the cactus? 3Unravelling new complexity in the genome 2Newly created cancer stem cells could aid breast cancer research 2Newly created cancer stem cells could aid breast cancer research 3
D.R. Harper (1993) • Includes: essential information on taxonomy, culture and safe handling of viruses, immunology, monoclonal antibodies, antivirals and vaccines....
...
... Purification Kits provide rapid and efficient removal ... products, and salts from PCR products (Figure ... provides two Binding Buffer options for fragments ... be performed in either single column or ...
... Zero Blunt TOPO PCR ... fastest and easiest method ... or equal to95%) cloning ... amplified with proofreading thermostable ...
Biology Products: